What type of study is this?

This is a Cohort Study study (also classified as: Experimental Study).

September 28, 2025Anticancer Research

High Claudin 18.2 Expression Predicts Favorable Outcomes in Pancreatic Ductal Adenocarcinoma After Curative Resection

View Full Paper

Ask AI

Bookmark

High claudin 18.2 expression is associated with better survival outcomes in pancreatic ductal adenocarcinoma patients.
Among 95 PDAC cases, 21% exhibited high claudin 18.2 expression linked to improved tumor differentiation and lower N stage.
Immunohistochemistry yielded a significant correlation of high claudin 18.2 expression with lower lymphatic invasion and better recurrence-free survival.
The findings suggest that claudin 18.2 could serve as both a therapeutic and prognostic marker, particularly for patients receiving adjuvant chemotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational analysis shows high claudin 18.2 expression correlates with improved survival in pancreatic ductal adenocarcinoma, highlighting its potential as a prognostic marker.

Cite This Study

Cha et al. (2025) studied this question.

synapsesocial.com/papers/68d9393b00263befa47b301e https://doi.org/10.21873/anticanres.17802

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis shows high claudin 18.2 expression correlates with improved survival in pancreatic ductal adenocarcinoma, highlighting its potential as a prognostic marker.

High Claudin 18.2 Expression Predicts Favorable Outcomes in Pancreatic Ductal Adenocarcinoma After Curative Resection

Key Points

Discussion

Implication

Cite This Study

High Claudin 18.2 Expression Predicts Favorable Outcomes in Pancreatic Ductal Adenocarcinoma After Curative Resection

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider